[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339809-105":59,"doc-detail-339809-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","an-analysis-of-the-trends-in-the-usage-of-pharmaceutical-benefits-schemesubsidised-cancer-drugs-in-australia-from-2012-to-2022","An analysis of the trends in the usage of Pharmaceutical Benefits Scheme‑subsidised cancer drugs in Australia from 2012 to 2022","","Purpose Cancer treatment drives substantial and rising healthcare expenses worldwide, yet how shifting treatment guidelines and new drug introductions will affect future budgeting remains unclear. This study examines trends in the use of Pharmaceutical Benefits Scheme (PBS)-subsidised cancer drugs in Australia across the past decade. Methods PBS codes for all PBS-subsidised cancer drugs listed in government-endorsed treatment protocols were used to extract usage data, analyzing prescription numbers from 2012–2022.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-analysis-of-the-trends-in-the-usage-of-pharmaceutical-benefits-schemesubsidised-cancer-drugs-in-australia-from-2012-to-2022/339809/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-analysis-of-the-trends-in-the-usage-of-pharmaceutical-benefits-schemesubsidised-cancer-drugs-in-australia-from-2012-to-2022/339809.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of analyzing PBS-subsidised cancer drug usage?","Question",{"text":112,"@type":113},"To examine how the use of PBS-subsidised cancer drugs in Australia has changed over the past decade and to clarify implications for future budgeting under evolving guidance and new drugs.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were usage trends measured in the study?",{"text":117,"@type":113},"By obtaining PBS codes for cancer drugs listed in government-endorsed treatment protocols from eviQ and analyzing prescription counts processed by Services Australia from 2012 to 2022.",{"name":119,"@type":110,"acceptedAnswer":120},"Which drug categories showed the largest increase in use?",{"text":121,"@type":113},"Kinase inhibitor drugs and monoclonal antibody drugs increased the most during the study period, with hormonal agents being the most prescribed among the reported classes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339809,1790508317,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Journal of Cancer Research and Clinical Oncology (2024) 150:375  \n[https://doi.org/10.1007/s00432-024-05889-x](https://doi.org/10.1007/s00432-024-05889-x)  \nAn analysis of the trends in the usage of Pharmaceutical Benefits Scheme‑subsidised cancer drugs in Australia from 2012 to 2022  \nJasmine Lee1 · Anastasios Panagiotelis2 · Rose Cairns1,3 · Nial J. Wheate4  \nReceived: 31 May 2024 / Accepted: 12 July 2024 / Published online: 31 July 2024 © The Author(s) 2024  \nAbstract  \nPurpose Cancer treatment remains a significant and escalating healthcare expense worldwide. Although annual reports on total cancer care costs are available, the potential impact of evolving treatment guidelines and the introduction of new drugs on future budgeting remains largely uncertain. The aim of this study was to examine the trends in the use of Pharmaceutical Benefits Scheme (PBS)-subsidised cancer drugs in Australia over the past decade.  \nMethods PBS codes for all PBS-subsidised cancer drugs that were listed in government-endorsed treatment protocols were obtained and used to retrieve usage data. Their patterns of use, represented by the number of prescriptions (services) processed by Services Australia, were analysed for the period between 2012 and 2022.  \nResults The overall prescribing of cancer drugs is outpacing Australia’s population growth, primarily due to an ageing population and the accelerated rise in cancer diagnoses observed over the past decade. From 846 eviQ protocols, 141 cancer drugs were available on the PBS, of which kinase inhibitor (39 drugs) and monoclonal antibody drugs (24 drugs) had the highest increase in use during the study period; 16% and 23% respectively. Of the 8 drug classes, hormonal agents (20 drugs) were the most prescribed.  \nConclusion The utilisation of PBS-listed cancer drugs is increasing faster than population growth, especially for high-cost monoclonal antibody and kinase inhibitor drugs, indicating continued pressure on government spending.  \nKeywords Cancer · Chemotherapy · Drugs · eviQ · Medicare · Australia  \nIntroduction  \nCancer continues to be a debilitating disease, ranking among the leading causes of death worldwide and imposing substantial health and economic challenges, particularly in high-income countries (Springer et al. 2024 ; Sullivan et al. 2011) . This burden is reflected in Australia, where more than 100,000 individuals are diagnosed each year (Australian  \n* Nial J. Wheate[nial.wheate@mq.edu.au](nial.wheate@mq.edu.au)  \n1 School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia  \n2 The University of Sydney Business School, Sydney, NSW, Australia  \n3 New South Wales Poisons Information Centre, The Children’s Hospital at Westmead, Sydney, NSW, Australia  \n4 School of Natural Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, Australia  \nInstitute of Health and Welfare 2023) . Treatment for cancer usually takes a tailored approach and can involve any, or a combination, of surgery, radiation therapy, or drug therapies. The use of cancer drugs remains widespread, since they are often used in neo-adjuvant and adjuvant therapy, before and after surgery, and are the preferred method for the treatment of metastatic cancers (Cancer Australia 2024 ; Australian Institute of Health and Welfare 2023) . The different types of drug therapy can include chemotherapy (cytotoxics), immunotherapy, hormonal therapy, and targeted therapy.  \nEstablished in 2009 under the auspices of the government-funded Cancer Institute New South Wales, eviQ stands as an Australian online resource aimed at bolstering nationwide cancer control amidst evolving care systems (eviQ 2024 ; Langton and Pearson 2011) . Developed by multidisciplinary teams and drawn from evidence-based practices, its tailored protocols for diverse cancer types and stages seamlessly integrate into clinical practice to guide healthcare professionals towards optimal cancer care. Whi","cbCaim24kQ8Y5WPz","https://ap.wps.com/l/cbCaim24kQ8Y5WPz","pdf",1227416,11,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Cancer burden in Australia\n## eviQ and cancer treatment protocols\n# Methods\n## eviQ protocols","[{\"question\":\"What was the purpose of analyzing PBS-subsidised cancer drug usage?\",\"answer\":\"To examine how the use of PBS-subsidised cancer drugs in Australia has changed over the past decade and to clarify implications for future budgeting under evolving guidance and new drugs.\"},{\"question\":\"How were usage trends measured in the study?\",\"answer\":\"By obtaining PBS codes for cancer drugs listed in government-endorsed treatment protocols from eviQ and analyzing prescription counts processed by Services Australia from 2012 to 2022.\"},{\"question\":\"Which drug categories showed the largest increase in use?\",\"answer\":\"Kinase inhibitor drugs and monoclonal antibody drugs increased the most during the study period, with hormonal agents being the most prescribed among the reported classes.\"}]","An analysis of the trends in the usage of Pharmaceutical Benefits Scheme‑subsidised cancer drugs in Australia from 2012 to 2022 | PDF",1790032366,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd58dce369b64fe62fee75105c30107f.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ade5272dc101af7d37641cc0d43d86f.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc297fa9834e4ca07670549baaa9448b.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fabb258dc6b23d72e2dfcfece5dd7461.webp",980,1301]